Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the
third quarter 2013. Revenues for the quarter totalled SEK 517 M (464), an
increase of 12 per cent. Kineret® and Partner Products showed strong performance
in the quarter. The company reconfirmed its outlook for the year.
Business Highlights
* Entered into a collaboration agreement for XIAPEX® in 71 European, Asian and
African countries with Auxilium Pharmaceuticals, Inc.
* Acquired full rights for Kineret and additional clinical data for Kepivance®
from Amgen
* Expanded the COMETRIQ® territories for which Sobi is responsible
* Received positive CHMP opinion for Kineret for treatment of rare disease
CAPS
* Submitted application for Orfadin® oral suspension to EMA and FDA
Financial Highlights
* Total revenues were SEK 517 M (464)
* Gross margin was 59 per cent (57) for the quarter
* Ended the quarter with a cash position of SEK 449 M
* Outlook for 2013 remains unchanged
"The third quarter for Sobi demonstrated solid progress in operational
performance, business development, and in the advancement of our pipeline.
Revenue for the overall portfolio grew by 12 per cent compared to last year,
with Kineret and Partner Products showing strong performance in the quarter. Our
margins are evolving as expected and we are making good progress financially
with a stable cash position and improved profitability from operations," said
Geoffrey McDonough, CEO and President.
---
Sobi's report for the third quarter 2013 can be found on
http://www.sobi.com/Investors--Media/Reports/
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late-stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70Â 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8Â 697 2135
oskar.bosson@sobi.com jorgen.winroth@sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 30 October 2013, at 8:00 CET
Sobi Complete Interim Report Jan-Sep, 2013:
http://hugin.info/134557/R/1739058/583605.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1739058]
